share_log

HC Wainwright Lowers ProQR Therapeutics (NASDAQ:PRQR) Price Target to $1.50

Financial News Live ·  Aug 15, 2022 10:01

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) had its price objective dropped by equities research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 71.62% from the company's previous close.

Several other research firms have also recently issued reports on PRQR. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target for the company in a research report on Friday. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.93.

Get ProQR Therapeutics alerts:

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $0.87 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.18. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The company has a market cap of $62.31 million, a PE ratio of -0.86 and a beta of 0.80.

Institutional Trading of ProQR Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $80,000. Coastal Bridge Advisors LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $85,000. Daiwa Securities Group Inc. lifted its stake in shares of ProQR Therapeutics by 22.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 2,352 shares in the last quarter. Corton Capital Inc. acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $280,000. Finally, Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at about $48,000.

ProQR Therapeutics Company Profile

(Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.

Read More

  • Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
  • The Five Hottest Calls From The Q2 Earnings Season
  • Here is a Simple 4 Stock Portfolio that Can Outperform the Market
  • Is AMC Entertainment Pulling a Fast One on the APEs?
  • Here's How the Inflation Reduction Act Energizes Power Stock
  • 2 Important Retail Stock Battles to Watch

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment